Citeline is the industry’s most comprehensive, reliable and current global R&D intelligence suite of solutions. Built by experts, made for experts, Citeline solutions transform data into knowledge. And now our new, next generation platform delivers unparalleled access to Citeline’s robust clinical trial intelligence. With greater ease, speed and efficiency than ever before, Citeline’s next generation platform will help you gain critical insights into the global clinical trial landscape and realize greater cost-savings as you develop on your clinical trial programs.
What Citeline does:
Citeline organizes vast quantities of data with human intelligence to greatly reduce research time, clinical trial costs and optimize trial outcomes. It features an unmatched collection of critical information on global clinical trials, investigators and sites, and drug development pipelines all with direct expert analyst support. Stay updated on what your competitors are doing with full public domain coverage of over 40,000 sources, continuous updating and full record reviews, advanced indexing and proprietary content.
Gain key insights that can be turned into actionable results with unparalleled access to 265,000+ clinical trials, 400,000 investigators, 68,000+ drugs, 117,000+ sites, 235+ diseases in 8 major therapeutic areas across 166 countries. And our 250+ therapeutic area experts and analysts are dedicated to provide the support needed so that you’re getting the most appropriate data to meet your requirements.
Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.
To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.
Citeline, Pink Sheet
Rising costs, patient recruitment issues, shifting regulations, and more are making bringing new drugs to market more difficult than ever. Explore changes in clinical trial design being adopted in response to these challenges with reporting from Pink Sheet.
KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.
With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.
For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.
Citeline, Sitetrove, Trialtrove, Pharmaprojects
Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.
The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, this article reviews trial benchmarks within the active oncology therapeutic area. Industry-sponsored clinical trials across all oncology indications covered by Informa Pharma Intelligence’s Trialtrove were assessed, comparing metrics by company size based on pharma sales, and the identical benchmarks for breast cancer and rare cancers were also analyzed.
Take the analysis from the Informa Pharma Intelligence R&D Annual Review 2019 further with the Pharma R&D Annual Review 2019 Supplement: New Active Substances Launched During 2018. This essential whitepaper uses critical data from Pharmaprojects to examine the new entities that were successfully launched to market last year.
Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.
The fourth annual CARE Awards returned to Boston, Massachusetts 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.
Topic Clinical trials
Citeline, Scrip, Pharmaprojects
April 17, 2019, Pharma R&D Review: What Changed In 2018, What To Look Out For In 2019
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: